Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012.
Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012.
复制标题
DOI：
10.3201/eid2109.141841
复制
发表时间：
2015-09
影响因子：
11.8
通讯作者：
Hpv-Impact Working Group
中科院分区：
文献类型：
--
作者：
Hariri S;Markowitz LE;Bennett NM;Niccolai LM;Schafer S;Bloch K;Park IU;Scahill MW;Julian P;Abdullah N;Levine D;Whitney E;Unger ER;Steinau M;Bauer HM;Meek J;Hadler J;Sosa L;Powell SE;Johnson ML;Hpv-Impact Working Group
为监测HPV疫苗接种效果，建立了宫颈癌前病变及相关类型的监测方法。2007年，五个新发感染计划(EIP)站点获得资助，以确定建立以人群为基础的监测系统的可行性，以监测人类乳头瘤病毒(HPV)疫苗对宫颈侵袭前病变的效果。该项目涉及以人口为基础积极监测宫颈上皮内瘤变2级和3级、原位腺癌以及居住在特定集水区的18岁妇女中的相关HPV类型；收集18-39岁妇女的相关临床信息和详细的HPV疫苗接种历史；以及估计集水区人口中宫颈癌筛查的年比率。该项目的头几年在疫苗引进的预期效果之前提供了关键信息，包括关于HPV型分布的数据。该项目的成功体现了EIP网络的灵活性，可以扩大核心活动，将急性传染病以外的新出现的监测需求包括在内。项目成果提供了有关美国HPV疫苗接种影响的关键信息。
Methods for surveillance of cervical precancers and associated types were developed to monitor effect of HPV vaccination. In 2007, five Emerging Infections Program (EIP) sites were funded to determine the feasibility of establishing a population-based surveillance system for monitoring the effect of human papillomavirus (HPV) vaccine on pre-invasive cervical lesions. The project involved active population-based surveillance of cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma in situ as well as associated HPV types in women >18 years of age residing in defined catchment areas; collecting relevant clinical information and detailed HPV vaccination histories for women 18–39 years of age; and estimating the annual rate of cervical cancer screening among the catchment area population. The first few years of the project provided key information, including data on HPV type distribution, before expected effect of vaccine introduction. The project’s success exemplifies the flexibility of EIP’s network to expand core activities to include emerging surveillance needs beyond acute infectious diseases. Project results contribute key information regarding the impact of HPV vaccination in the United States.